Progress toward the Development of Glycan-Based Vaccines against Campylobacteriosis

ACS Infect Dis. 2021 May 14;7(5):969-986. doi: 10.1021/acsinfecdis.0c00332. Epub 2020 Jul 9.

Abstract

As one of the main causes of bacterial diarrhea and a major risk factor for triggering Guillain-Barré autoimmune syndrome, campylobacteriosis, that is, Campylobacter spp. infections, represents a major health issue worldwide. There is thus a pressing need for developing an effective and broad-coverage campylobacteriosis vaccine. Campylobacter jejuni, an encapsulated, multidrug resistant Gram-negative bacterium, expresses virulence-associated capsular polysaccharides (CPSs), which constitute exquisite targets for the design of glycoconjugate vaccines. In that context, synthetic carbohydrate chemistry acts as a crucial enabling technology for the preparation of homogeneous constructs while allowing antigenic epitopes to be deciphered and probed at the molecular level. This review aims at covering recent developments in CPS-based campylobacteriosis vaccines as well as in the total syntheses of C. jejuni-related mono- and oligosaccharide mimics.

Keywords: Campylobacter jejuni; campylobacteriosis; capsular polysaccharides; glycoconjugate vaccines; oligosaccharide synthesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Bacterial Vaccines
  • Campylobacter Infections* / prevention & control
  • Campylobacter jejuni*
  • Glycoconjugates
  • Humans
  • Polysaccharides

Substances

  • Bacterial Vaccines
  • Glycoconjugates
  • Polysaccharides